Result of AGM and Consolidation of Share Capital (3606C)
April 30 2012 - 6:45AM
UK Regulatory
TIDMNGG
RNS Number : 3606C
NextGen Group PLC
30 April 2012
NextGen Group Plc
("NextGen" or "the Company")
Result of Annual General Meeting and Consolidation of Share
Capital
NextGen Group plc (AIM: NGG), an AIM listed company providing
biomarker discovery services and diagnostic assay development,
announces that at the Company's Annual General Meeting, which was
held today, all the resolutions proposed were duly passed with more
than 99% in favour of each resolution.
Following shareholder approval at the AGM, the Company's
ordinary share capital will be consolidated with effect from close
of business tonight such that every 500 existing ordinary shares of
0.1p will be consolidated into one ordinary share of 50p.
Accordingly there will be 14,493,578 ordinary 50p shares in issue
and application has been made to AIM for 14,493,578 ordinary shares
of 50p each to be admitted to trading on AIM with effect from 1 May
2012. The ISIN for the new ordinary shares of 50p each is
GB00B7JRYW03.
The figure of 14,493,578 may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change to their
interest in, the Company under the FSA's Disclosure and
Transparency Rules.
For further details please contact:
NextGen Group
Klaus Rosenau, Chairman
+49 160 5516756
Seymour Pierce
Jonathan Wright, Nicola Marrin
+44 20 7107 8000
About NextGen
NextGen (AIM: NGG), the biomarker specialists, provide services
to pharmaceutical and biotech companies globally. Using advanced
techniques, such as Multiple Reaction Monitoring (MRM) mass
spectrometry analysis, the Company is developing a portfolio of
robust assays for testing clinical samples for drug safety and
efficacy, and the development of personalized treatment for
patients. NextGen Sciences' range of services, which include
biomarker testing, discovery and assay development, are employed by
its customers as a key part of the biomarker-based drug and
diagnostic development process. For more information visit
www.nextgensciences.com
NextGen Group PLC floated on the AIM market in London in
December 2005 raising GBP2.4 million in an oversubscribed offering
which included strong institutional investor support from Germany
as well as in the UK. Further details relating to NextGen Group PLC
and its products can be found at www.nextgensciences.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
RAGFBLFXLZFZBBF
Nextgen (LSE:NGG)
Historical Stock Chart
From Dec 2024 to Jan 2025
Nextgen (LSE:NGG)
Historical Stock Chart
From Jan 2024 to Jan 2025
